NCT00589381View on ClinicalTrials.gov

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

fenretinide lipid matrix

Trial Locations (4)

33308

Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

90027-0700

Childrens Hospital Los Angeles, Los Angeles

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00589381 - Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter